CN110520441B8 - 抗TGF-β抗体及其用途 - Google Patents

抗TGF-β抗体及其用途 Download PDF

Info

Publication number
CN110520441B8
CN110520441B8 CN201880007975.3A CN201880007975A CN110520441B8 CN 110520441 B8 CN110520441 B8 CN 110520441B8 CN 201880007975 A CN201880007975 A CN 201880007975A CN 110520441 B8 CN110520441 B8 CN 110520441B8
Authority
CN
China
Prior art keywords
tgf
antibodies
antibody
diseases
immunomodulators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880007975.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN110520441A (zh
CN110520441B (zh
Inventor
G·夏皮罗
K·布劳恩
P·费恩
R·C·格雷戈里
R·科杜里
刘锋
N·马尔科娃
P·曼库
J·R·波拉德
邱华伟
J·泰拉伯
C·温特
俞翠琤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Priority to CN202311230922.7A priority Critical patent/CN117417939A/zh
Priority claimed from PCT/IB2018/000088 external-priority patent/WO2018134681A1/en
Publication of CN110520441A publication Critical patent/CN110520441A/zh
Application granted granted Critical
Publication of CN110520441B publication Critical patent/CN110520441B/zh
Publication of CN110520441B8 publication Critical patent/CN110520441B8/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201880007975.3A 2017-01-20 2018-01-19 抗TGF-β抗体及其用途 Active CN110520441B8 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311230922.7A CN117417939A (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762448800P 2017-01-20 2017-01-20
EP17305061 2017-01-20
US62/448,800 2017-01-20
EP17305061.8 2017-01-20
EP1730561.8 2017-01-20
PCT/IB2018/000088 WO2018134681A1 (en) 2017-01-20 2018-01-19 Anti-tgf-beta antibodies and their use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311230922.7A Division CN117417939A (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途

Publications (3)

Publication Number Publication Date
CN110520441A CN110520441A (zh) 2019-11-29
CN110520441B CN110520441B (zh) 2023-11-14
CN110520441B8 true CN110520441B8 (zh) 2024-07-09

Family

ID=61656071

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880007975.3A Active CN110520441B8 (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途
CN202311230922.7A Pending CN117417939A (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311230922.7A Pending CN117417939A (zh) 2017-01-20 2018-01-19 抗TGF-β抗体及其用途

Country Status (21)

Country Link
US (4) US10766955B2 (enExample)
JP (3) JP7213186B2 (enExample)
CN (2) CN110520441B8 (enExample)
AU (2) AU2018209391B2 (enExample)
BR (1) BR112019014787A2 (enExample)
CA (1) CA3050845A1 (enExample)
CL (1) CL2019002011A1 (enExample)
CO (1) CO2019008946A2 (enExample)
CR (1) CR20190375A (enExample)
DO (1) DOP2019000191A (enExample)
EC (1) ECSP19059553A (enExample)
IL (3) IL268112B2 (enExample)
MA (1) MA47311A (enExample)
MX (2) MX2019008551A (enExample)
MY (1) MY200751A (enExample)
PE (1) PE20200734A1 (enExample)
PH (1) PH12019501635A1 (enExample)
SG (1) SG11201906660TA (enExample)
TW (3) TWI787230B (enExample)
UY (1) UY37575A (enExample)
ZA (1) ZA201904494B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
AU2019301283B2 (en) * 2018-07-10 2024-12-19 Sanofi Combination therapies against cancer targeting CD38 and TGF-beta
KR20250160211A (ko) 2018-08-30 2025-11-11 이뮤니티바이오, 인크. 다중-사슬 키메라 폴리펩타이드 및 이의 용도
CN113365663B (zh) 2018-08-30 2025-11-21 免疫生物公司 单链嵌合多肽和其用途
KR20210117271A (ko) * 2018-12-21 2021-09-28 노쓰웨스턴유니버시티 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
EP3739588A1 (en) * 2019-05-13 2020-11-18 Koninklijke Philips N.V. Assessment of multiple signaling pathway activity score in airway epithelial cells to predict airway epithelial abnormality and airway cancer risk
US11738052B2 (en) 2019-06-21 2023-08-29 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
KR20220140535A (ko) 2020-02-11 2022-10-18 에이치씨더블유 바이올로직스, 인크. 크로마토그래피 수지 및 이의 용도
CA3169231A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of treating age-related and inflammatory diseases
WO2021163298A1 (en) 2020-02-11 2021-08-19 HCW Biologics, Inc. Methods of activating regulatory t cells
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
JP7734693B2 (ja) 2020-04-29 2025-09-05 イミュニティーバイオ インコーポレイテッド 抗ｃｄ２６タンパク質及びそれらの使用法
US12024545B2 (en) 2020-06-01 2024-07-02 HCW Biologics, Inc. Methods of treating aging-related disorders
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
IL309310A (en) * 2021-06-18 2024-02-01 Genzyme Corp Antibody formulations against TGF-beta and their use
JP2024532760A (ja) 2021-08-11 2024-09-10 エイチシーダブリュー バイオロジックス インコーポレイテッド 多重鎖キメラポリペプチド及び肝疾患の治療におけるその使用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
TW202334209A (zh) * 2021-11-01 2023-09-01 美商健臻公司 成骨不全症之治療
JP2025513831A (ja) 2022-04-13 2025-04-30 イミュニティバイオ，インコーポレーテッド 神経炎症性障害の処置における使用のための多重鎖キメラポリペプチド
KR20250004747A (ko) 2022-04-13 2025-01-08 이뮤니티바이오, 인크. 생체 시계 유전자 장애의 치료에 사용하기 위한 다중-사슬 키메라 폴리펩티드
CN115508565B (zh) * 2022-10-20 2024-11-15 成都医学院第一附属医院 Cilp1作为肾纤维化生物标志物的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229028A (zh) * 2013-03-20 2016-01-06 建新公司 用于治疗成骨不全的方法
CN105934253A (zh) * 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
CN106068275A (zh) * 2014-01-23 2016-11-02 瑞泽恩制药公司 抗pd‑1的人抗体

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0672142B1 (en) 1992-12-04 2001-02-28 Medical Research Council Multivalent and multispecific binding proteins, their manufacture and use
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
BRPI9707379C8 (pt) 1996-02-09 2017-12-12 Abbott Biotech Ltd composições farmacêuticas compreendendo anticorpo humano recombinante geneticamente engenheirado, e anticorpo humano recombinante geneticamente engenheirado.
WO1998035703A2 (en) 1997-02-14 1998-08-20 The Salk Institute For Biological Studies Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
MY131805A (en) 1997-09-18 2007-09-28 Biogen Idec Inc Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis.
EP1074563A1 (en) 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20020063763A1 (en) 2000-11-29 2002-05-30 Mantell David Allen Apparatus and method for removing air bubbles from an ink jet printhead
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
NZ554885A (en) 2002-12-31 2009-07-31 Altus Pharmaceuticals Inc Complexes of hgh crystals and protamine polymers
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
EP1646655A2 (en) 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
WO2005097832A2 (en) 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies
ES2887039T3 (es) 2004-04-21 2021-12-21 Alexion Pharma Inc Conjugados para administración ósea y procedimiento de uso de estos para dirigir proteínas al hueso
ES2711213T3 (es) 2005-02-08 2019-04-30 Genzyme Corp Anticuerpos de TGFbeta
TW200714289A (en) 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2688275A1 (en) * 2007-05-31 2008-12-04 Genmab A/S Stable igg4 antibodies
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
CN115043946A (zh) 2008-01-03 2022-09-13 斯克里普斯研究院 通过模块识别结构域的抗体靶向
RS54233B1 (sr) 2008-08-25 2015-12-31 Amplimmune Inc. Kompozicije pd-1 antagonista i postupci za njihovu primenu
CA2745317C (en) 2008-12-22 2019-03-05 Ida Hilden Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
PL2542590T5 (pl) 2010-03-05 2020-08-10 The Johns Hopkins University Kompozycje i sposoby dla ukierunkowanych immunomodulatorowych przeciwciał i białek fuzyjnych
SI2691417T2 (sl) * 2011-03-29 2025-05-30 Roche Glycart Ag FC variante protitelesa
ES2669310T3 (es) 2011-04-20 2018-05-24 Medimmune, Llc Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
LT2714735T (lt) 2011-06-03 2021-12-10 Xoma Technology Ltd. Tgf beta specifiniai antikūnai
BR112013031892A2 (pt) 2011-06-13 2016-11-22 Abgenomics Cooperatief Ua anticorpos anti-psgl-1 e seu uso
WO2013058833A1 (en) 2011-10-19 2013-04-25 Enobia Canada Limited Partnership Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
DK2855527T3 (en) 2012-05-31 2018-11-26 Innate Pharma TLR3 BINDERS
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
PT3702373T (pt) 2013-09-13 2022-09-27 Beigene Switzerland Gmbh Anticorpos anti-pd1 e a sua utilização como agentes terapêuticos e de diagnóstico
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
US20170216401A1 (en) 2014-03-17 2017-08-03 Piotr Jachimczak Combination for use in a method of treating cancer
US20180265874A1 (en) 2014-10-10 2018-09-20 Global Biopharma, Inc. Methods for treating and/or preventing a tumor growth, invasion and/or metastasis
CA2964367C (en) * 2014-10-14 2024-01-30 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
EP3250250A4 (en) 2015-01-30 2019-05-22 President and Fellows of Harvard College PERITUMORAL AND INTRATUMORAL MATERIALS FOR CANCER THERAPY
TWI733661B (zh) * 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
CN108136001B (zh) * 2015-04-03 2022-07-29 佐马技术有限公司 使用TGF-β抑制剂和PD-1抑制剂治疗癌症
ES2813580T3 (es) 2015-04-17 2021-03-24 Bristol Myers Squibb Co Composiciones que comprenden una combinación de ipilimumab y nivolumab
WO2017011773A2 (en) 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
WO2017037634A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-β-receptor ectodomain fusion molecules and uses thereof
AU2017310344A1 (en) 2016-08-11 2019-03-07 Precithera, Inc. TGF-β antagonist conjugates
TW202421659A (zh) 2017-01-20 2024-06-01 美商健臻公司 骨靶向抗體
TWI787230B (zh) 2017-01-20 2022-12-21 法商賽諾菲公司 抗ＴＧＦ-β抗體及其用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105229028A (zh) * 2013-03-20 2016-01-06 建新公司 用于治疗成骨不全的方法
CN105934253A (zh) * 2013-12-17 2016-09-07 豪夫迈·罗氏有限公司 使用pd-1轴结合拮抗剂和抗her2抗体治疗her2阳性癌症的方法
CN106068275A (zh) * 2014-01-23 2016-11-02 瑞泽恩制药公司 抗pd‑1的人抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
基于单克隆抗体的肿瘤免疫疗法研究进展;郭亚军;《生物工程学报》;20150625;第31卷(第6期);第863页第3.2节 *

Also Published As

Publication number Publication date
US11242384B2 (en) 2022-02-08
IL323799A (en) 2025-12-01
JP2020514310A (ja) 2020-05-21
TW202313678A (zh) 2023-04-01
US10766955B2 (en) 2020-09-08
JP7213186B2 (ja) 2023-01-26
TW202506185A (zh) 2025-02-16
DOP2019000191A (es) 2019-10-15
AU2024264593A1 (en) 2024-12-05
UY37575A (es) 2018-10-31
CN117417939A8 (zh) 2024-07-12
IL268112A (en) 2019-09-26
IL268112B1 (en) 2025-05-01
US20250026821A1 (en) 2025-01-23
PE20200734A1 (es) 2020-07-23
NZ756431A (en) 2025-03-28
CO2019008946A2 (es) 2019-09-30
US20220195026A1 (en) 2022-06-23
CN110520441A (zh) 2019-11-29
IL311866A (en) 2024-06-01
TW201833135A (zh) 2018-09-16
JP2023052376A (ja) 2023-04-11
TWI787230B (zh) 2022-12-21
CA3050845A1 (en) 2018-07-26
US20200399358A1 (en) 2020-12-24
AU2018209391B2 (en) 2024-08-15
MA47311A (fr) 2019-11-27
ZA201904494B (en) 2020-12-23
CN110520441B (zh) 2023-11-14
MY200751A (en) 2024-01-13
TWI856437B (zh) 2024-09-21
US20180244763A1 (en) 2018-08-30
IL268112B2 (en) 2025-09-01
CR20190375A (es) 2019-12-17
CN117417939A (zh) 2024-01-19
AU2018209391A1 (en) 2019-09-05
CL2019002011A1 (es) 2019-11-22
IL311866B1 (en) 2025-11-01
US12049496B2 (en) 2024-07-30
SG11201906660TA (en) 2019-08-27
ECSP19059553A (es) 2019-08-30
MX2023002588A (es) 2023-03-22
MX2019008551A (es) 2020-01-27
JP7411832B2 (ja) 2024-01-11
PH12019501635A1 (en) 2019-11-04
JP2024038040A (ja) 2024-03-19
BR112019014787A2 (pt) 2020-02-27

Similar Documents

Publication Publication Date Title
CN110520441B8 (zh) 抗TGF-β抗体及其用途
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
PH12020550243A1 (en) Anti-tau antibodies and uses thereof
ZA201708265B (en) Tigit-binding agents and uses thereof
EA202091540A1 (ru) Антитела к lilrb2
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
MX2020000960A (es) Anticuerpos anti-tigit.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
PH12018502502A1 (en) Anti-gitr antibodies and uses thereof
WO2018081648A3 (en) ANTI-MIC ANTIBODIES AND METHODS OF USE
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
CO2017004516A2 (es) Anticuerpos anti-ox40 humanizados
WO2015197598A3 (en) Multispecific antigen binding proteins
WO2016086189A3 (en) Heterodimeric antibodies that bind cd3 and tumor antigens
WO2016077381A8 (en) Anti-interleukin-33 antibodies and uses thereof
WO2015112886A3 (en) Binding proteins and methods of use thereof
WO2016086175A8 (en) Effector-deficient anti-cd32a antibodies
WO2018134681A8 (en) Anti-tgf-beta antibodies and their use
TR201810635T4 (tr) Anti-jagged1 antikorları ve kullanım yöntemleri.
WO2018031490A3 (en) Anti-ox40 binding proteins
WO2018069871A3 (en) Anti-kras binding proteins
WO2017049038A3 (en) Anti-cd115 antibodies
WO2015153997A3 (en) Notch3 antibodies and uses thereof
WO2018018039A3 (en) Glucocorticoid-induced tumor necrosis factor receptor (gitr) antibodies and methods of use thereof
WO2018071504A3 (en) Methods of treating diseases with il-23a antibody

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CI03 Correction of invention patent

Correction item: Priority

Correct: 17305061.8 2017.01.20 EP|62/448,800 2017.01.20 US

False: 1730561.8 2017.01.20 EP|62/448,800 2017.01.20 US

Number: 46-01

Page: The title page

Volume: 39

Correction item: Priority

Correct: 17305061.8 2017.01.20 EP|62/448,800 2017.01.20 US

False: 1730561.8 2017.01.20 EP|62/448,800 2017.01.20 US

Volume: 39

CI03 Correction of invention patent
TG01 Patent term adjustment
TG01 Patent term adjustment